Article

Lack of Maternal Folic Acid Supplementation Is Associated with Heart Defects in Down Syndrome: A Report from the National Down Syndrome Project

Department of Human Genetics, Emory University, Atlanta, Georgia, USA.
Birth Defects Research Part A Clinical and Molecular Teratology (Impact Factor: 2.09). 10/2011; 91(10):885-93. DOI: 10.1002/bdra.22848
Source: PubMed

ABSTRACT

Maternal folic acid supplementation has been associated with a reduced risk for neural tube defects and may be associated with a reduced risk for congenital heart defects and other birth defects. Individuals with Down syndrome are at high risk for congenital heart defects and have been shown to have abnormal folate metabolism.
As part of the population-based case-control National Down Syndrome Project, 1011 mothers of infants with Down syndrome reported their use of supplements containing folic acid. These data were used to determine whether a lack of periconceptional maternal folic acid supplementation is associated with congenital heart defects in Down syndrome. We used logistic regression to test the relationship between maternal folic acid supplementation and the frequency of specific heart defects correcting for maternal race or ethnicity, proband sex, maternal use of alcohol and cigarettes, and maternal age at conception.
Lack of maternal folic acid supplementation was more frequent among infants with Down syndrome and atrioventricular septal defects (odds ratio [OR], 1.69; 95% confidence interval [CI], 1.08-2.63; p = 0.011) or atrial septal defects (OR, 1.69; 95% CI, 1.11-2.58; p = 0.007) than among infants with Down syndrome and no heart defect. Preliminary evidence suggests that the patterns of association differ by race or ethnicity and sex of the proband. There was no statistically significant association with ventricular septal defects (OR, 1.26; 95% CI, 0.85-1.87; p = 0.124).
Our results suggest that lack of maternal folic acid supplementation is associated with septal defects in infants with Down syndrome. Birth Defects Research (Part A), 2011. © 2011 Wiley-Liss, Inc.

Download full-text

Full-text

Available from: Stuart Tinker
  • Source
    • "Thus, the dysregulation of pathways involved in heart development may cause the cardiac defects observed in DS. A second hypothesis implicating both environmental and genetic factors in DS phenotypes is supported by epidemiological studies of DS: specific cardiac defects were associated with smoking mothers (AVSD, TOF) [17], [18], folate pathways and folate supplementation have been proposed to interfere with the incidence of AVSD [19], [20], and an association between DS and CHD with global hypomethylation status has been found in a Dutch population-based case-control study [21]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Forty percent of people with Down syndrome exhibit heart defects, most often an atrioventricular septal defect (AVSD) and less frequently a ventricular septal defect (VSD) or atrial septal defect (ASD). Lymphoblastoid cell lines (LCLs) were established from lymphocytes of individuals with trisomy 21, the chromosomal abnormality causing Down syndrome. Gene expression profiles generated from DNA microarrays of LCLs from individuals without heart defects (CHD(-); n = 22) were compared with those of LCLs from patients with cardiac malformations (CHD(+); n = 21). After quantile normalization, principal component analysis revealed that AVSD carriers could be distinguished from a combined group of ASD or VSD (ASD+VSD) carriers. From 9,758 expressed genes, we identified 889 and 1,016 genes differentially expressed between CHD(-) and AVSD and CHD(-) and ASD+VSD, respectively, with only 119 genes in common. A specific chromosomal enrichment was found in each group of affected genes. Among the differentially expressed genes, more than 65% are expressed in human or mouse fetal heart tissues (GEO dataset). Additional LCLs from new groups of AVSD and ASD+VSD patients were analyzed by quantitative PCR; observed expression ratios were similar to microarray results. Analysis of GO categories revealed enrichment of genes from pathways regulating clathrin-mediated endocytosis in patients with AVSD and of genes involved in semaphorin-plexin-driven cardiogenesis and the formation of cytoplasmic microtubules in patients with ASD-VSD. A pathway-oriented search revealed enrichment in the ciliome for both groups and a specific enrichment in Hedgehog and Jak-stat pathways among ASD+VSD patients. These genes or related pathways are therefore potentially involved in normal cardiogenesis as well as in cardiac malformations observed in individuals with trisomy 21.
    Full-text · Article · Aug 2012 · PLoS ONE
  • [Show abstract] [Hide abstract]
    ABSTRACT: Down syndrome (DS) is the most common genetic cause of mental retardation. Clinical manifestations are variable, and children have psychomotor impairment, multiple malformations, and medical conditions. Confirmation of the diagnosis is by karyotype analysis. The cytogenetic abnormality can be classified into pure trisomy 21, translocation, or mosaicism. Risk of recurrence depends on the primary cytogenetic abnormality in the proband. Prenatal screening is by biochemical and ultrasound markers in the first and second trimester. Definitive prenatal diagnosis is by analysis of fetal chromosomes in fetal chorionic villi, amniocytes, or cord blood. A noninvasive test for trisomy 21 in maternal blood has been developed by massively parallel shotgun sequencing. Therapeutic studies in Ts65Dn mice suggest an exciting prospect of improvement of learning ability and memory deficits.
    No preview · Article · Jun 2012 · Clinics in laboratory medicine
  • [Show abstract] [Hide abstract]
    ABSTRACT: Trisomy 21 is the genetic basis of Down syndrome (DS), the most common human chromosomal disorder. DS phenotype may include several dysmorphic features, intellectual disability, immunological alteration, congenital heart disease, high risk for specific types of leukemia and neurological alterations. There are basically two hypotheses to explain how the presence of three copies of chromosome 21 results in DS phenotype. The "gene dosage effect" hypothesis states that over-expression in about 50% of a specific gene or a group of genes located on chromosome 21 present in triplicate in DS individuals is directly responsible for DS features. The second hypothesis suggests the existence of secondary effects of trissomic genes that affect multiple metabolic pathways, resulting in cellular dysfunction. Studies have shown that regulatory mechanisms of gene expression are also altered in trisomy 21, such as changes in DNA methylation pattern, that regulates the transcription of DNA into RNA, and differential expression of microRNAs, small molecules of noncoding RNA involved in post-transcriptional gene regulation. Alterations in mechanisms that control the gene expression in DS individuals could result in abnormal expression of specific proteins and contribute to DS phenotype. In addition, DS individuals present abnormal folate metabolism leading to alterations in metabolites involved in this pathway. Elevated concentrations of homocysteine, an amino acid essential for folate-dependent DNA synthesis and for cellular methylation reactions, important for fetal development, for example, was associated with DS fetal survival and reduced intelligence quotient (IQ). Considering the importance in identifying the mechanisms that contribute to DS phenotype, this book chapter will aim to present the literature data concerning changes in the folate metabolism and in the pattern and control of gene expression of DS individuals that could be associated with biological processes relevant to DS physiopathology.
    No preview · Article · Sep 2012
Show more